Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Post by TawiTwaion Jan 18, 2023 2:44am
416 Views
Post# 35229815

The SBM Webinar: Conclusion

The SBM Webinar: Conclusion

A lot was said without anything being really said. But reading between the lines here is what I am getting at. 

 

First the question regarding replacement for CEO: He said he will not stand in the way, meaning he is willing to step down if there is the right candidate. Fact is that they are looking, but they are not going to find anyone unless they deliver on AbbVie or animal health deal. No competent CEO will join the company unless there is a guaranteed revenue stream. Further a good CEO is not going to be cheap in a full time capacity :) 

 

I think it is clear from their responses, that pretty much everything is on ice as of right now until money comes into the door. External advisors, marketing and management additions or replacement. That is also the reason why he was somewhat evasive on some of the questions. They are focusing on getting the animal deal done, because that would mean upfront and miles-stone payments. 

 

All the questions regarding the AbbVie deal, pretty much evaporated, as their confidentiality agreement does not allow them to talk about it, they can not discuss or answer details of the deal. We can only speculate on the royalty payments and how high they will be, what will be the estimated total revenue of 1067 etc.... 

 

Chris: He was pretty upfront about it, looks like down the road there will be some sort of financing..... unless there is money from the animal health or AbbVie coming in. Dilution of 270 million shares already ... looks like we will be approaching the 300 million barrier. 

 

I agree that it is good to have these webinars. However I think we should pool the questions in advance and come up with 5 key questions that we all want to have answered. So we can focus on the important things....


<< Previous
Bullboard Posts
Next >>